IP Library Granted Patent US 8,790,641
Granted Patent B2
US 8,790,641 · App. 12/385,894 · Granted Jul 29, 2014

Production of high mannose proteins in plant culture and therapeutic uses thereof

Inventors: Yoseph Shaaltiel (Kibbutz HaSolelim-Doar-Na HaMovil, IL); Gideon Baum (D.N. Upper Galilee, IL); Daniel Bartfeld (Moran-Doar-Na Bikat Beit HaKerem, IL); Sharon Hashmueli (Ramot-Naftali, IL); Ayala Lewkowicz (Kfar-Vradim, IL)
Assignee: Protalix Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,641
App. No.
12/385,894
Granted
Jul 29, 2014
Kind
B2
Abstract

A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

Claims (15)

1. A method for treating a subject having Gaucher's disease using exogenous human glucocerebrosidase protein, the method comprising administering a therapeutically effective amount of a glucocerebrosidase protein to said subject, wherein said human glucocerebrosidase protein is as set forth in SEQ ID NO: 15, thereby treating said Gaucher's disease in said subject.

2. The method of claim 1 , wherein said human glucocerebrosidase protein is glycosylated with at least one xylose and at least one exposed mannose residue.

3. The method of claim 1 , wherein said human glucocerebrosidase protein is glycosylated with at least one core α-(1,2) xylose and at least one core α-(1,3) fucose.

4. The method of claim 3 , wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue.

5. The method of claim 1 , wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue and at least one fucose residue having an alpha (1-3) glycosidic bond.

6. The method of claim 2 , wherein said xylose residue is a core α-(1,2) xylose residue.

7. The method of claim 2 , wherein said glucocerebrosidase protein binds to a mannose receptor on a macrophage.

8. The method of claim 4 , wherein said glucocerebrosidase protein binds to a mannose receptor on a macrophage.

9. The method of claim 7 , wherein said glucocerebrosidase is taken up into macrophages.

10. The method of claim 9 , wherein said human glucocerebrosidase protein having an increased uptake by said macrophages, in comparison with the corresponding macrophage uptake of a recombinant glucocerebrosidase expressed in mammalian cells.

11. The method of claim 6 , wherein the main glycan structure of said therapeutically effective amount of said human glucocerebrosidase protein is glycosylation with one exposed mannose residue.

12. A method of increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of a subject in need thereof, the method comprising administering a therapeutically effective amount of a human glucocerebrosidase protein to said subject, wherein said human glucocerebrosidase protein is as set forth in SEQ ID NO: 15, thereby increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of said subject.

13. The method of claim 12 , wherein said human glucocerebrosidase protein is glycosylated with at least one xylose and at least one exposed mannose residue.

14. The method of claim 12 , wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue and at least one fucose residue having an alpha (1-3) glycosidic bond.

15. The method of claim 12 , wherein the main glycan structure of said therapeutically effective amount of said human glucocerebrosidase protein is glycosylation with one exposed mannose residue.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 6, 2024
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: PROTALIX LTD.
Reel/Frame 068856/0589 →
SECURITY INTEREST Recorded Sep 3, 2021
From: PROTALIX LTD.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 057383/0155 →
SECURITY INTEREST Recorded Dec 12, 2016
From: PROTALIX LTD.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 040708/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2014
From: SHAALTIEL, YOSEPH; BAUM, GIDEON; BARTFELD, DANIEL; HASHMUELI, SHARON; LEWKOWICZ, AYALA
To: PROTALIX LTD.
Reel/Frame 032556/0650 →
Priority Claims (1)
IL 155588 · Apr 27, 2003 · national
Continuity (3)
Division 11790991 · Apr 30, 2007
Continuation In Part 10554387
Related Publication 20090208477A1 · Aug 20, 2009